Belgian biopharmaceutical company Oxurion NV (Euronext Brussels:OXUR) revealed on Thursday that it has secured financing from Atlas Special Opportunities to acquire 72% of the share capital of French biometrics specialist Axiodis CRO
The transaction is expected to close on 1 August 2025, following successful due diligence and the satisfaction of all conditions precedent.
This acquisition aligns with Oxurion's strategy to build an integrated clinical data platform supporting key stages of therapeutic development.
Oxurion aims to leverage Axiodis' human and technical expertise to strengthen its position as a strategic partner in clinical research.
The company has also identified additional acquisition targets in France and across Europe to support its ambition of creating a leading European clinical data hub.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA